{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T19:56:03Z","timestamp":1785268563821,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Background factors for <jats:italic>Candida<\/jats:italic> spp. detection in urine include indwelling urinary catheters, diabetes mellitus, and a history of antimicrobial exposure; nevertheless, urinary tract infections caused by <jats:italic>Candida<\/jats:italic> spp. are usually rare. Fluconazole (FLCZ) is a preferable drug for the treatment of urinary tract infections caused by <jats:italic>Candida<\/jats:italic> spp.; however, some cases of urinary tract candidiasis resistant to FLCZ have been observed, making the selection of a therapeutic agent difficult. Recently, an increase in fungal genital infections has been reported alongside the increase in the use of sodium glucose cotransporter 2 (SGLT2) inhibitors. Although these medications have not been shown to increase urinary tract infections, concerns persist that they may promote colonization of the genital tract by <jats:italic>Candida<\/jats:italic> spp. and cause retrograde urinary tract infections, particularly in women. This is a rare case of <jats:italic>Candida glabrata<\/jats:italic> induced pyelonephritis and bacteremia in a patient receiving SGLT2 inhibitors, successfully treated with micafungin (MCFG).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>A patient in her 70s under active treatment for breast cancer was diagnosed with a urinary tract infection and bacteremia caused by <jats:italic>C. glabrata<\/jats:italic>. The patient was taking SGLT2 inhibitors, and had no history of urinary catheter placement or antimicrobial exposure. In order to avoid the side effects of amphotericin B (AmB) and flucytosine (5-FC), the patient was treated with MCFG and FLCZ for 17 days. No adverse events or recurrence were recorded over the subsequent three months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Patients taking SGLT2 inhibitors may be more susceptible to urinary tract infections caused by <jats:italic>Candida glabrata<\/jats:italic>, and in cases of azole-resistant <jats:italic>Candida<\/jats:italic> spp. urinary tract infection, MCFG may be a treatment option when AmB or 5-FC is difficult to use.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40780-025-00475-w","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T08:13:33Z","timestamp":1754381613000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A case of pyelonephritis and bacteremia caused by Candida glabrata in a patient on sodium glucose cotransporter 2 inhibitor, successfully treated with micafungin"],"prefix":"10.1186","volume":"11","author":[{"given":"Shoko","family":"Sahara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruhisa","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Takimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"issue":"3","key":"475_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1086\/519268","volume":"45","author":"CA Czaja","year":"2007","unstructured":"Czaja CA, Scholes D, Hooton TM, Stamm WE. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis. 2007;45(3):273\u201380. https:\/\/doi.org\/10.1086\/519268.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 6","key":"475_CR2","doi-asserted-by":"publisher","first-page":"S433","DOI":"10.1093\/cid\/cir109","volume":"52","author":"JD Sobel","year":"2011","unstructured":"Sobel JD, Fisher JF, Kauffman CA, Newman CA. Candida urinary tract infections \u2014 Epidemiology. Clin Infect Dis. 2011;52(Suppl 6):S433\u20136. https:\/\/doi.org\/10.1093\/cid\/cir109.","journal-title":"Clin Infect Dis"},{"key":"475_CR3","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44:3627\u201339. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195.","journal-title":"Eur Heart J"},{"key":"475_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102:S1\u2013127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008.","journal-title":"Kidney Int"},{"key":"475_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.pcd.2017.06.004","volume":"12","author":"KY Thong","year":"2018","unstructured":"Thong KY, Yadagiri M, Barnes DJ, Morris DS, Chowdhury TA, Chuah LL, et al. Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: the ABCD nationwide Dapagliflozin audit. Prim Care Diabetes. 2018;12:45\u201350. https:\/\/doi.org\/10.1016\/j.pcd.2017.06.004.","journal-title":"Prim Care Diabetes"},{"key":"475_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1086\/313583","volume":"30","author":"CA Kauffman","year":"2000","unstructured":"Kauffman CA, Vazquez JA, Sobel JD, Gallis HA, McKinsey DS, Karchmer AW, et al. Prospective multicenter surveillance study of Funguria in hospitalized patients. The National Institute for allergy and infectious diseases (NIAID) mycoses study group. Clin Infect Dis. 2000;30:14\u20138. https:\/\/doi.org\/10.1086\/313583.","journal-title":"Clin Infect Dis"},{"key":"475_CR7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","volume":"62","author":"PG Pappas","year":"2016","unstructured":"Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guidelines for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62:e1\u201350. https:\/\/doi.org\/10.1093\/cid\/civ933.","journal-title":"Clin Infect Dis"},{"key":"475_CR8","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium","year":"2022","unstructured":"Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400:1788\u2013801. https:\/\/doi.org\/10.1016\/S0140-6736(22)02074-8.","journal-title":"Lancet"},{"key":"475_CR9","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1590\/S1678-9946202466071","volume":"66","author":"MA T\u00fcz","year":"2024","unstructured":"T\u00fcz MA, Ecer DT, Atik TK, Yap\u0131c\u0131 O. Scrotal abscess caused by Candida glabrata in a patient with uncontrolled diabetes mellitus and chronic renal failure. Rev Inst Med Trop Sao Paulo. 2024;66:e71. https:\/\/doi.org\/10.1590\/S1678-9946202466071.","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"475_CR10","doi-asserted-by":"publisher","first-page":"1408646","DOI":"10.3389\/fmed.2024.1408646","volume":"11","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Cai Y, Yang Y, Xu C, Xiang J, Fang Z, Mao S. The mystery of abdominal snow-grip sensation: emphysematous cystitis complicated with bladder gangrene and rupture\u2014case report and literature review. Front Med (Lausanne). 2024;11:1408646. https:\/\/doi.org\/10.3389\/fmed.2024.1408646.","journal-title":"Front Med (Lausanne)"},{"key":"475_CR11","doi-asserted-by":"publisher","first-page":"100649","DOI":"10.1016\/j.mmcr.2024.100649","volume":"44","author":"KJ Villegas","year":"2024","unstructured":"Villegas KJ, Orhun N, Vera Garces S, Ozgur SS, Michael P, Zahran A, Rabinowitz D. Unilateral renal fungus ball caused by Candida glabrata. Med Mycol Case Rep. 2024;44:100649. https:\/\/doi.org\/10.1016\/j.mmcr.2024.100649.","journal-title":"Med Mycol Case Rep"},{"key":"475_CR12","doi-asserted-by":"publisher","first-page":"D7268","DOI":"10.1007\/s40278-024-70201-1","volume":"167","author":"AM Zeelenberg","year":"2023","unstructured":"Zeelenberg AM, van der Wielen GJ, Beishuizen ED, Hetem DJ. Urineweginfectie door Candida Bijgebruik SGLT2-remmer. Ned TijdschrGeneeskd. 2023;167:D7268. https:\/\/doi.org\/10.1007\/s40278-024-70201-1.","journal-title":"Ned TijdschrGeneeskd"},{"issue":"20","key":"475_CR13","doi-asserted-by":"publisher","first-page":"e33798","DOI":"10.1097\/MD.0000000000033798","volume":"102","author":"R Deng","year":"2023","unstructured":"Deng R, Meng X, Li R, Wang A, Song Y. Asymptomatic Candida glabrata urinary tract infection in an immunocompetent young female: a case report. Med (Baltim). 2023;102(20):e33798. https:\/\/doi.org\/10.1097\/MD.0000000000033798.","journal-title":"Med (Baltim)"},{"key":"475_CR14","doi-asserted-by":"publisher","first-page":"794235","DOI":"10.3389\/fonc.2021.794235","volume":"11","author":"M Szymankiewicz","year":"2021","unstructured":"Szymankiewicz M, Kamecki K, Jarzynka S, Koryszewska-Bagi\u0144ska A, Ol\u0119dzka G, Nowikiewicz T. Case report: echinocandin-resistance Candida glabrata FKS mutants from patient following radical cystoprostatectomy due to muscle-invasive bladder cancer. Front Oncol. 2021;11:794235. https:\/\/doi.org\/10.3389\/fonc.2021.794235.","journal-title":"Front Oncol"},{"issue":"4","key":"475_CR15","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s13730-021-00616-8","volume":"10","author":"A Woloshuk","year":"2021","unstructured":"Woloshuk A, Lee M, Assmus M, Agarwal D, Krambeck A, Large T. A case of ureteral fungal mass removal in a patient taking empagliflozin. CEN Case Rep. 2021;10(4):603\u20137. https:\/\/doi.org\/10.1007\/s13730-021-00616-8.","journal-title":"CEN Case Rep"},{"key":"475_CR16","doi-asserted-by":"publisher","first-page":"e01176","DOI":"10.1016\/j.idcr.2021.e01176","volume":"25","author":"J Nagata","year":"2021","unstructured":"Nagata J, Kawasaki T, Iesato K, Sugiura T, Yamauchi K, Tsuyusaki J, et al. A case of candidemia after long-term presence of urethral foreign bodies. IDCases. 2021;25:e01176. https:\/\/doi.org\/10.1016\/j.idcr.2021.e01176.","journal-title":"IDCases"},{"issue":"6","key":"475_CR17","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1159\/000507259","volume":"144","author":"C Cases-Corona","year":"2020","unstructured":"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno de la Higuera MA, Lucena R, et al. Fulminant emphysematous pyelonephritis byCandida glabrata in a kidney allograft. Nephron. 2020;144(6):304\u20139. https:\/\/doi.org\/10.1159\/000507259.","journal-title":"Nephron"},{"issue":"8","key":"475_CR18","first-page":"516","volume":"53","author":"M Rahimkhani","year":"2015","unstructured":"Rahimkhani M, Saberian M, Mordadi A, Varmazyar S, Tavakoli A. Urinary tract infection with Candida glabrata in a patient with spinal cord injury. Acta Med Iran. 2015;53(8):516\u20137.","journal-title":"Acta Med Iran"},{"issue":"1","key":"475_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.5152\/eajm.2011.14","volume":"43","author":"II Balkan","year":"2011","unstructured":"Balkan II, Savas A, Geduk A, Yemisen M, Mete B, Ozaras R. Candida glabrata perinephric abscess. Eurasian J Med. 2011;43(1):63\u20135. https:\/\/doi.org\/10.5152\/eajm.2011.14.","journal-title":"Eurasian J Med"},{"issue":"6","key":"475_CR20","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.nephro.2010.05.005","volume":"6","author":"H Harrabi","year":"2010","unstructured":"Harrabi H, Marrakchi C, Daoud E, Elleuch E, Hammami B, Ma\u00e2loul I, et al. La py\u00e9lon\u00e9phrite emphys\u00e9mateuse bilat\u00e9rale \u00e0 Candida glabrata: Une entit\u00e9 exceptionnelle [Bilateral emphysematous pyelonephritis caused by Candida glabrata: an exceptional entity]. Nephrol Ther. 2010;6(6):541\u20133. https:\/\/doi.org\/10.1016\/j.nephro.2010.05.005.","journal-title":"Nephrol Ther"},{"issue":"2","key":"475_CR21","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1155\/2007\/768734","volume":"18","author":"D Lagrotteria","year":"2007","unstructured":"Lagrotteria D, Rotstein C, Lee CH. Treatment of Candiduria with micafungin: a case series. Can J Infect Dis Med Microbiol. 2007;18(2):149\u201350. https:\/\/doi.org\/10.1155\/2007\/768734.","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"475_CR22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/1471-2334-6-126","volume":"6","author":"S Schelenz","year":"2006","unstructured":"Schelenz S, Ross CN. Limitations of Caspofungin in the treatment of obstructive pyonephrosis due to Candida glabrata infection. BMC Infect Dis. 2006;6:126. https:\/\/doi.org\/10.1186\/1471-2334-6-126.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"475_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.diabres.2013.12.052","volume":"103","author":"S Geerlings","year":"2014","unstructured":"Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract. 2014;103(3):373\u201381. https:\/\/doi.org\/10.1016\/j.diabres.2013.12.052.","journal-title":"Diabetes Res Clin Pract"},{"issue":"10","key":"475_CR24","doi-asserted-by":"publisher","first-page":"809","DOI":"10.4239\/wjd.v13.i10.809","volume":"13","author":"J Talapko","year":"2022","unstructured":"Talapko J, Me\u0161trovi\u0107 T, \u0160krlec I. Growing importance of urogenital candidiasis in individuals with diabetes: a narrative review. World J Diabetes. 2022;13(10):809\u201321. https:\/\/doi.org\/10.4239\/wjd.v13.i10.809.","journal-title":"World J Diabetes"},{"issue":"1","key":"475_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/02681218780000061","volume":"25","author":"CE Webster","year":"1987","unstructured":"Webster CE, Odds FC. Growth of pathogenic Candida isolates anaerobically and under elevated concentrations of CO2 in air. J Med Vet Mycol. 1987;25(1):47\u201353. https:\/\/doi.org\/10.1080\/02681218780000061.","journal-title":"J Med Vet Mycol"},{"issue":"2","key":"475_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.critrevonc.2011.03.002","volume":"81","author":"U Swami","year":"2012","unstructured":"Swami U, Chaudhary I, Ghalib MH, Goel S. Eribulin\u2014a review of preclinical and clinical studies. Crit Rev Oncol Hematol. 2012;81(2):163\u201384. https:\/\/doi.org\/10.1016\/j.critrevonc.2011.03.002.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9769","key":"475_CR27","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O\u2019Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. EMBRACE (Eisai metastatic breast cancer study assessing physician\u2019s choice versus E7389) investigators. Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914\u201323. https:\/\/doi.org\/10.1016\/S0140-6736(11)60070-6.","journal-title":"Lancet"},{"issue":"Suppl 6","key":"475_CR28","doi-asserted-by":"publisher","first-page":"S457","DOI":"10.1093\/cid\/cir112","volume":"52","author":"JF Fisher","year":"2011","unstructured":"Fisher JF, Sobel JD, Kauffman CA, Newman CA. Candida urinary tract infections \u2014 Treatment. Clin Infect Dis. 2011;52(Suppl 6):S457\u201366. https:\/\/doi.org\/10.1093\/cid\/cir112.","journal-title":"Clin Infect Dis"},{"key":"475_CR29","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1093\/cid\/cix033","volume":"64","author":"G Cuervo","year":"2017","unstructured":"Cuervo G, Garcia-Vidal C, Puig-Asensio M, Vena A, Meije Y, Fern\u00e1ndez-Ruiz M, et al. Echinocandins compared to fluconazole for candidemia of a urinary tract source: a propensity score analysis. Clin Infect Dis. 2017;64:1374\u20139. https:\/\/doi.org\/10.1093\/cid\/cix033.","journal-title":"Clin Infect Dis"},{"key":"475_CR30","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ijantimicag.2016.05.010","volume":"48","author":"S Grau","year":"2016","unstructured":"Grau S, Luque S, Echeverr\u00eda-Esnal D, Sorl\u00ed L, Campillo N, Montero M, et al. Urinary Micafungin levels are sufficient to treat urinary tract infections caused by Candida spp. Int J Antimicrob Agents. 2016;48:212\u20134. https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.05.010.","journal-title":"Int J Antimicrob Agents"},{"key":"475_CR31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1128\/CMR.00046-13","volume":"27","author":"T Felton","year":"2014","unstructured":"Felton T, Troke PF, Hope WW. Tissue penetration of antifungal agents. Clin Microbiol Rev. 2014;27:68\u201388. https:\/\/doi.org\/10.1128\/CMR.00046-13.","journal-title":"Clin Microbiol Rev"},{"key":"475_CR32","volume-title":"Performance standards for antifungal susceptibility testing of yeasts: M27M44S","author":"Clinical and Laboratory Standards Institute","year":"2022","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antifungal susceptibility testing of yeasts: M27M44S. 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2022.","edition":"3"},{"issue":"2","key":"475_CR33","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1128\/CMR.19.2.435-447.2006","volume":"19","author":"MA Pfaller","year":"2006","unstructured":"Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev. 2006;19(2):435\u201347. https:\/\/doi.org\/10.1128\/CMR.19.2.435-447.2006.","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"475_CR34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1365-2125.1990.tb03623.x","volume":"29","author":"S Toon","year":"1990","unstructured":"Toon S, Ross CE, Gokal R, Rowland M. An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole. Br J Clin Pharmacol. 1990;29(2):221\u20136. https:\/\/doi.org\/10.1111\/j.1365-2125.1990.tb03623.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"475_CR35","doi-asserted-by":"publisher","first-page":"249","DOI":"10.7326\/0003-4819-109-3-249_1","volume":"109","author":"F Leroy","year":"1988","unstructured":"Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C. Dihydroergotamine-erythromycin-induced ergotism. Ann Intern Med. 1988;109(3):249. https:\/\/doi.org\/10.7326\/0003-4819-109-3-249_1.","journal-title":"Ann Intern Med"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00475-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-025-00475-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00475-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T20:06:31Z","timestamp":1754424391000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-025-00475-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["475"],"URL":"https:\/\/doi.org\/10.1186\/s40780-025-00475-w","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"21 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the Ethics Committee of Kariya Toyota General Hospital (approval number 1103).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of anonymized information.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}